Nature Communications (Jul 2020)
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
- Meenakshi Hegde,
- Sujith K. Joseph,
- Farzana Pashankar,
- Christopher DeRenzo,
- Khaled Sanber,
- Shoba Navai,
- Tiara T. Byrd,
- John Hicks,
- Mina L. Xu,
- Claudia Gerken,
- Mamta Kalra,
- Catherine Robertson,
- Huimin Zhang,
- Ankita Shree,
- Birju Mehta,
- Olga Dakhova,
- Vita S. Salsman,
- Bambi Grilley,
- Adrian Gee,
- Gianpietro Dotti,
- Helen E. Heslop,
- Malcolm K. Brenner,
- Winfried S. Wels,
- Stephen Gottschalk,
- Nabil Ahmed
Affiliations
- Meenakshi Hegde
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Sujith K. Joseph
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Farzana Pashankar
- Department of Pediatrics, Yale University School of Medicine
- Christopher DeRenzo
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Khaled Sanber
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Shoba Navai
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Tiara T. Byrd
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- John Hicks
- Department of Pathology and Immunology, Baylor College of Medicine
- Mina L. Xu
- Department of Pathology, Yale University School of Medicine
- Claudia Gerken
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Mamta Kalra
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Catherine Robertson
- Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine
- Huimin Zhang
- Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine
- Ankita Shree
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Birju Mehta
- Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine
- Olga Dakhova
- Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine
- Vita S. Salsman
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Bambi Grilley
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Adrian Gee
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Gianpietro Dotti
- Department of Microbiology and Immunology at University of North Carolina
- Helen E. Heslop
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Malcolm K. Brenner
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Winfried S. Wels
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy
- Stephen Gottschalk
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- Nabil Ahmed
- Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-17175-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
Recurrent metastatic rhabdomyosarcoma remains largely incurable. Here, the authors describe a child with metastatic rhabdomyosarcoma who has durable response to HER2-specific CAR T cells and shows endogenous immune reactivity.
